CL2025001309A1 - Formulaciones orales compactables de ibutamoren - Google Patents
Formulaciones orales compactables de ibutamorenInfo
- Publication number
- CL2025001309A1 CL2025001309A1 CL2025001309A CL2025001309A CL2025001309A1 CL 2025001309 A1 CL2025001309 A1 CL 2025001309A1 CL 2025001309 A CL2025001309 A CL 2025001309A CL 2025001309 A CL2025001309 A CL 2025001309A CL 2025001309 A1 CL2025001309 A1 CL 2025001309A1
- Authority
- CL
- Chile
- Prior art keywords
- ibutamoren
- compactable
- oral formulations
- administration
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263422329P | 2022-11-03 | 2022-11-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2025001309A1 true CL2025001309A1 (es) | 2025-09-26 |
Family
ID=90835855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2025001309A CL2025001309A1 (es) | 2022-11-03 | 2025-05-02 | Formulaciones orales compactables de ibutamoren |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11969416B1 (enExample) |
| EP (1) | EP4611737A1 (enExample) |
| JP (2) | JP2025535941A (enExample) |
| KR (1) | KR20250107210A (enExample) |
| CN (1) | CN120239602A (enExample) |
| AU (1) | AU2022485048A1 (enExample) |
| CL (1) | CL2025001309A1 (enExample) |
| CO (1) | CO2025007025A2 (enExample) |
| GE (1) | GEAP202516774A (enExample) |
| IL (1) | IL320529A (enExample) |
| MX (1) | MX2025005154A (enExample) |
| WO (1) | WO2024096892A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11969416B1 (en) | 2022-11-03 | 2024-04-30 | Lumos Pharma, Inc. | Compactable oral formulations of ibutamoren |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5128143A (en) * | 1988-09-19 | 1992-07-07 | Edward Mendell Co., Inc. | Sustained release excipient and tablet formulation |
| CA2234817A1 (en) | 1995-10-27 | 1997-05-01 | Mandana Asgharnejad | Wet granulation formulation of a growth hormone secretagogue |
| US6123964A (en) | 1995-10-27 | 2000-09-26 | Merck & Co., Inc. | Wet granulation formulation of a growth hormone secretagogue |
| MXPA03001771A (es) * | 2000-08-30 | 2003-06-04 | Pfizer Prod Inc | Formulaciones de liberacion sostenida para secretagogos de hormona del crecimiento. |
| AU2003225102A1 (en) * | 2002-04-23 | 2003-11-10 | Bristol-Myers Squibb Company | Modified-release vasopeptidase inhibitor formulation, combinations and method |
| JP5336349B2 (ja) | 2006-03-15 | 2013-11-06 | マイケル・オー・ソーナー | 成長ホルモン分泌促進物質による筋肉減少症の処置方法 |
| FI20080351A0 (fi) | 2008-05-09 | 2008-05-09 | Atacama Labs Oy | Prosessi matalan lääkepitoisuuden tabletin valmistamiseksi |
| WO2014030204A1 (ja) * | 2012-08-20 | 2014-02-27 | 大日本住友製薬株式会社 | 薬物含有中空粒子 |
| KR102499918B1 (ko) | 2012-10-24 | 2023-02-14 | 다이이찌 산쿄 가부시키가이샤 | 근위축성 측삭 경화증 치료제 |
| CN105530935A (zh) * | 2013-03-14 | 2016-04-27 | 红山生物医药有限公司 | 抗呕吐缓释固体剂型 |
| CA2845443A1 (en) * | 2014-03-04 | 2015-09-04 | Pharmascience Inc. | Orally disintegrating tablet of nabilone and method of manufacturing |
| KR20230116961A (ko) | 2015-09-21 | 2023-08-04 | 암모네트 파마 엘엘씨 | 성장 호르몬 결핍의 검출 및 치료 |
| KR20200121308A (ko) * | 2018-02-14 | 2020-10-23 | 루모스 파마, 인크. | 비알코올성 지방간 질환 및 비알코올성 지방간염 치료용 조성물 |
| US11969416B1 (en) | 2022-11-03 | 2024-04-30 | Lumos Pharma, Inc. | Compactable oral formulations of ibutamoren |
-
2022
- 2022-11-22 US US18/057,941 patent/US11969416B1/en active Active
- 2022-11-22 CN CN202280101646.1A patent/CN120239602A/zh active Pending
- 2022-11-22 AU AU2022485048A patent/AU2022485048A1/en active Pending
- 2022-11-22 WO PCT/US2022/050700 patent/WO2024096892A1/en not_active Ceased
- 2022-11-22 IL IL320529A patent/IL320529A/en unknown
- 2022-11-22 JP JP2025523885A patent/JP2025535941A/ja active Pending
- 2022-11-22 EP EP22964610.4A patent/EP4611737A1/en active Pending
- 2022-11-22 GE GEAP202516774A patent/GEAP202516774A/en unknown
- 2022-11-22 KR KR1020257018282A patent/KR20250107210A/ko active Pending
-
2024
- 2024-04-01 US US18/623,761 patent/US12390452B2/en active Active
-
2025
- 2025-05-02 CL CL2025001309A patent/CL2025001309A1/es unknown
- 2025-05-02 MX MX2025005154A patent/MX2025005154A/es unknown
- 2025-05-27 CO CONC2025/0007025A patent/CO2025007025A2/es unknown
- 2025-11-12 JP JP2025191860A patent/JP2026027432A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20250107210A (ko) | 2025-07-11 |
| WO2024096892A1 (en) | 2024-05-10 |
| JP2026027432A (ja) | 2026-02-18 |
| US11969416B1 (en) | 2024-04-30 |
| GEAP202516774A (en) | 2025-06-25 |
| US20240156793A1 (en) | 2024-05-16 |
| US20240245663A1 (en) | 2024-07-25 |
| CN120239602A (zh) | 2025-07-01 |
| AU2022485048A1 (en) | 2025-05-22 |
| CO2025007025A2 (es) | 2025-07-17 |
| EP4611737A1 (en) | 2025-09-10 |
| JP2025535941A (ja) | 2025-10-30 |
| MX2025005154A (es) | 2025-07-01 |
| IL320529A (en) | 2025-06-01 |
| US12390452B2 (en) | 2025-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP21051833A (es) | Combinación de dextrometorfano y bupropión para el tratamiento de depresión | |
| CO2026005655A2 (es) | Inhibidor de pan-kras y uso del mismo en medicinas | |
| ES2916649T1 (es) | Composiciones y usos para el tratamiento de la esclerosis múltiple | |
| MX2020003421A (es) | Metodos para la administracion de ciertos inhibidores del transportador vesicular de monoamina 2 (vmat2). | |
| AR048431A1 (es) | Formulaciones galenicas de compuestos organicos | |
| MX2015017307A (es) | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington. | |
| MX2016010179A (es) | Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer. | |
| PE20250018A1 (es) | Formas de dosificacion farmaceuticas que comprenden (4s)-24-cloro-4-etil-73-fluoro-35- metoxi-32 ,5-dioxo-14-(trifluorometil)-32h-6-aza-3(4,1)-piridina-1(1)-[1,2,3]triazola- 2(1,2),7(1)-dibencenaheptafano-74-carboxamida | |
| AR045289A1 (es) | Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento | |
| MX2021014774A (es) | Formulaciones de liberacion modificada y usos de las mismas. | |
| CO2025007025A2 (es) | Formulaciones orales compactables de ibutamoren | |
| MX2021014161A (es) | Metodos de tratamiento del sindrome de sjogren utilizando un inhibidor de la tirosina quinasa de bruton. | |
| DOP2025000146A (es) | Compuesto quimérico protac, método de preparación del mismo y uso del mismo | |
| MX2022015629A (es) | Uso de vibegron para tratar vejiga sobreactiva. | |
| BR112023026909A2 (pt) | Sal farmaceuticamente aceitável de ap1189 ((e)-n-[1-(2-nitrofenil)-1-h-pirrol-2-il-alilidenoamino]-guanidina), composição farmacêutica, forma de dosagem única, e, formulação oral | |
| AR108897A1 (es) | Una película de desintegración oral de acción rápida para la administración de anestesia local | |
| EP4635494A3 (en) | AMIDO HETERO-ROMATIC COMPOUNDS | |
| CO2022008616A2 (es) | Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma | |
| AR066666A1 (es) | Composicion farmaceutica que comprende la combinacion de un agente antiinflamatorio no esteroideo y un agente anticonvulsivante | |
| CL2025001901A1 (es) | Uso de pridopidina para el tratamiento de la enfermedad de huntington juvenil. | |
| AR101227A1 (es) | Combinaciones de un derivado de n-tiazolil-4-fenoxibencenosulfonamida y un agente farmacéuticamente activo seleccionado a partir de gabapentina y pregabalina para tratar dolor | |
| CO2022001574A2 (es) | Combinación sinérgica de s-ketorolaco y pregabalina en una composición farmacéutica para el tratamiento del dolor neuropático. | |
| MX2021006464A (es) | Forma polimorfica de meisoindigo y formulacion modificada de meisoindigo. | |
| CL2022000095A1 (es) | Composiciones farmacéuticas resistentes a la descarga de dosis que comprenden venirunad | |
| AR115994A1 (es) | Combinación farmacéutica sinérgica que comprende tramadol clorhidrato y pregabalina, y su uso para el tratamiento del dolor neuropático |